论文部分内容阅读
[目的]探讨灌注栓塞治疗原发性肝癌的临床疗效。[方法]60例原发性肝癌患者,分成观察组和对照组。对照组采用肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)治疗;观察组采用门静脉持续灌注化疗(portal vein infusion chemotherapy,PVC)配合TACE治疗。[结果]观察组总有效率为56.67%优于对照组总有效率30.00%,差异有统计学意义(P﹤0.05)。观察组1年生存率为66.67%高于对照组40.00%,差异有统计学意义(P﹤0.05)。[结论PVC配合TACE治疗原发性肝癌疗效佳,具有重要临床价值。
[Objective] To investigate the clinical efficacy of perfusion and embolization in the treatment of primary liver cancer. [Method] Sixty patients with primary liver cancer were divided into observation group and control group. The control group was treated with transcatheter arterial chemoembolization (TACE). The observation group was treated with portal vein infusion chemotherapy (PVC) combined with TACE. [Results] The total effective rate in observation group was 56.67%, which was better than that in control group. The total effective rate was 30.00%. The difference was statistically significant (P <0.05). The 1-year survival rate in the observation group was 66.67%, which was significantly higher than that in the control group (40.00%) (P <0.05). [Conclusion PVC with TACE treatment of primary liver cancer with good effect, has important clinical value.